** Shares of Unicycive Therapeutics rise ~1.9% to $1.63 premarket
** Co says the U.S. FDA has granted an "orphan" designation to its drug UNI-494 for the prevention of delayed graft function (DGF)
** DGF is a form of kidney failure and a common complication experienced by kidney transplant recipients
** Orphan drug status is given by the FDA to drugs that treat rare conditions and are protected through a series of government incentives once in market
** Up to last close, stock more than tripled in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments